ArticleFrontiers in oncology2021
Identification of an Aging-Related Gene Signature in Predicting Prognosis and Indicating Tumor Immune Microenvironment in Breast Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Construction and evaluation of a prognostic model for breast cancer based on aging related genes.Scientific reports · 2025Article
- Identification and Verification of a Prognostic Risk Signature in Oral Squamous Cell Carcinoma.Current topics in medicinal chemistry · 2025Article
- Data-independent Acquisition Mass Spectrometry Reveals Exosomal LAMC1 as a Key Determinant of Lung Adenocarcinoma Radiosensitivity, Independent of EGFR Mutation.Current pharmaceutical design · 2025Article
- Predictive model of gene expression regulating invasion and migration of M2 macrophages in breast cancer: clinical prognosis and therapeutic implications.Translational cancer research · 2024Article
- Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer.BMC genomics · 2024Article
- PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis.American journal of cancer research · 2024Article
- Immunotherapy targeting isoDGR-protein damage extends lifespan in a mouse model of protein deamidation.EMBO molecular medicine · 2023Article
- Identifying prognostic markers in spatially heterogeneous breast cancer microenvironment.Journal of translational medicine · 2023Article
- A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.Molecules (Basel, Switzerland) · 2023Article
- Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Construction and validation of an aging-related gene signature predicting the prognosis of pancreatic cancer.Frontiers in genetics · 2023Article
- Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most commonly diagnosed malignancy accompanied by high invasion and metastasis features. Importantly, emerging studies have supported that aging is a key clue that participates in the immune state and development of BC. Nevertheless, there are no studies concerning the aging-related genes (AGs) in constructing the prognosis signature of BC. Here, to address this issue, we initially performed a systematic investigation of the associations between AGs and BC prognosis and accordingly constructed a prognosis risk model with 10 AGs including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.